Merck’s Therapy Extends Survival in Hard-to-Treat Uterine Cancer Patients
Researchers said the infusion also cut tumour growth risk by 41% and shrank tumors in 35% of patients, compared with 17% on chemotherapy.
- On Monday, October 26, 2026, researchers presented phase 3 trial results at the European Society For Medical Oncology showing sacituzumab tirumotecan reduced death risk by 32% in patients with advanced endometrial cancer.
- Endometrial cancer incidence in UK women under 50 has doubled over 25 years, driven largely by the obesity epidemic and associated hormonal imbalances that experts say fuel rapid cell division.
- The trial involved 776 women with advanced disease; 35.1% treated with sac-TMT experienced tumor shrinkage versus 17.3% on standard chemotherapy, while the drug cut progression risk by 41%.
- Study principal investigator Dr. Bhavana Pothuri stated the results establish sac-TMT as a "new standard treatment" for recurrent endometrial cancer and suggest effectiveness against other cancers where Trop-2 protein is overexpressed.
- Merck is conducting 18 global Phase 3 studies, including 10 focused on women's cancers, to support regulatory approvals in the United States, Europe, and elsewhere outside China.
17 Articles
17 Articles
Merck Drug Boosts Survival From Hard-to-Treat Uterine Cancer
An experimental drug from Merck & Co. helped women with advanced endometrial cancer live significantly longer than those receiving chemotherapy, bolstering the company’s ambitions for the novel treatment it is studying in a wide range of tumors.
Merck's therapy extends survival in hard-to-treat uterine cancer ...
A new drug is effective in reducing the recurrence of endometrial cancer and mortality from this disease, according to an important international study published in 'The Lancet' Read
informacion.es
A new treatment for advanced or recurrent endometrial cancer has shown promising results in a phase 3 international clinical trial involving 776 women from around 30 countries. The drug has managed to reduce the risk of disease or death progression by 41% and the risk of death by 3%, compared to conventional chemotherapy, during the study period.
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
